A phase I/II feasibility vaccine study by autologous leukemic apoptotic corpse-pulsed dendritic cells for elderly AML patients - Archive ouverte HAL Access content directly
Journal Articles Human Vaccines & Immunotherapeutics Year : 2021

A phase I/II feasibility vaccine study by autologous leukemic apoptotic corpse-pulsed dendritic cells for elderly AML patients

(1, 2) , (3, 4, 5) , (6) , (1, 2) , (2) , (7, 3, 4) , (8) , (6, 9) , (10) , (7, 3, 4) , (11, 2) , (1, 11, 8) , (12)
1
2
3
4
5
6
7
8
9
10
11
12
Pierre Peterlin

Abstract

This was a phase I/II study testing the feasibility of a vaccine by autologous leukemic apoptotic corpse-pulsed dendritic cells (DC) in elderly acute myeloid leukemia (AML) patients in first or second complete remission. Pulsed DC were administered at doses of 9 × 106 subcutaneously (1 mL) and 1 × 106 intra-dermally (0.1 mL). Five doses of vaccine were planned on days +1 + 7 + 14 + 21 and +35. Five DC-vaccines were produced and injected for all five patients included in the study. No severe adverse event was documented. Larger Phase 2 studies are now required to precise the role of DC-vaccines with leukemic apoptotic bodies in older as well as younger AML populations.
Embargoed file
Embargoed file
Ne sera jamais visible

Dates and versions

inserm-03335625 , version 1 (06-09-2021)

Identifiers

Cite

Patrice Chevallier, Soraya Saiagh, Virginie Dehame, Thierry Guillaume, Pierre Peterlin, et al.. A phase I/II feasibility vaccine study by autologous leukemic apoptotic corpse-pulsed dendritic cells for elderly AML patients. Human Vaccines & Immunotherapeutics, 2021, Online ahead of print. ⟨10.1080/21645515.2021.1943991⟩. ⟨inserm-03335625⟩
27 View
18 Download

Altmetric

Share

Gmail Facebook Twitter LinkedIn More